Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
How to buy Bolt Biotherapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BOLT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Bolt Biotherapeutics stock price (NASDAQ: BOLT)
Use our graph to track the performance of BOLT stocks over time.Bolt Biotherapeutics shares at a glance
Latest market close | $1.52 |
---|---|
52-week range | $1.18 - $3.64 |
50-day moving average | $1.39 |
200-day moving average | $1.72 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.64 |
Buy Bolt Biotherapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Bolt Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bolt Biotherapeutics price performance over time
Historical closes compared with the close of $1.515 from 2023-02-06
1 week (2023-02-01) | 3.06% |
---|---|
1 month (2023-01-06) | 7.45% |
3 months (2022-11-08) | 17.44% |
6 months (2022-08-08) | -34.98% |
1 year (2022-02-04) | -55.83% |
---|---|
2 years (2021-02-08) | -95.35% |
3 years (2020-02-04) | N/A |
5 years (2018-02-04) | N/A |
Bolt Biotherapeutics financials
Revenue TTM | $4.8 million |
---|---|
Gross profit TTM | $-74,395,000 |
Return on assets TTM | -20.8% |
Return on equity TTM | -41.12% |
Profit margin | 0% |
Book value | $5.00 |
Market capitalisation | $55.4 million |
TTM: trailing 12 months
Bolt Biotherapeutics share dividends
We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.
Bolt Biotherapeutics overview
Bolt Biotherapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics in the news
Bolt Biotherapeutics to Present at February Investor Conferences
Bolt Biotherapeutics to Present at February Investor Conferences
Frequently asked questions
What percentage of Bolt Biotherapeutics is owned by insiders or institutions?Currently 6.55% of Bolt Biotherapeutics shares are held by insiders and 58.115% by institutions. How many people work for Bolt Biotherapeutics?
Latest data suggests 91 work at Bolt Biotherapeutics. When does the fiscal year end for Bolt Biotherapeutics?
Bolt Biotherapeutics's fiscal year ends in December. Where is Bolt Biotherapeutics based?
Bolt Biotherapeutics's address is: 900 Chesapeake Drive, Redwood City, CA, United States, 94063 What is Bolt Biotherapeutics's ISIN number?
Bolt Biotherapeutics's international securities identification number is: US0977021049
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert